Beginning in 2004, chikungunya virus (CHIKV) went from an endemic pathogen limited to Africa and Asia that caused periodic outbreaks to a global pathogen. Given that outbreaks caused by CHIKV have continued and expanded, serious consideration must be given to identifying potential options for vaccines and therapeutics. Currently, there are no licensed products in this realm, and control relies completely on the use of personal protective measures and integrated vector control, which are only minimally effective. Therefore, it is prudent to urgently examine further possibilities for control. Vaccines have been shown to be highly effective against vector-borne diseases. However, as CHIKV is known to rapidly spread and generate high attack rates, therapeutics would also be highly valuable. Several candidates are currently being developed; this review describes the multiple options under consideration for future development and assesses their relative advantages and disadvantages.

中文翻译：

---

控制基孔肯雅病毒的疫苗和治疗选择[评论]

从2004年开始，基孔肯雅病毒（CHIKV）从一种局限于非洲和亚洲的地方病原体传播，这种病原体导致了周期性的爆发，后来又演变为一种全球病原体。鉴于由CHIKV引起的暴发已经持续并扩大，必须认真考虑确定疫苗和治疗剂的潜在选择。当前，此领域中没有许可产品，控制完全依赖于个人防护措施和集成矢量控制的使用，而这些保护措施的有效性最低。因此，谨慎检查进一步的控制可能性是明智的。疫苗已被证明对媒介传播疾病非常有效。但是，由于已知CHIKV会迅速传播并产生高发作率，因此治疗方法也将具有很高的价值。目前正在开发一些候选人；